URL path: Index page // Influenza Virus B, Molecular Detection

Influenza Virus B, Molecular Detection

The molecular test for the presence of influenza type Β virus is used for the rapid and accurate laboratory confirmation of the infection. This screening is useful for early documentation of influenza, which allows rapid implementation of appropriate treatment and prevention measures.

More Information

Influenza virus type B is one of the three main types of influenza viruses, alongside type A and type C. While influenza A viruses can infect humans, birds, and other animals, type B viruses primarily circulate among humans and are less likely to cause pandemics compared to type A.

Genetic Characteristics: Influenza B viruses belong to the Orthomyxoviridae family and have a segmented RNA genome. They have a single subtype of hemagglutinin (HA) protein and one subtype of neuraminidase (NA) protein. Unlike type A viruses, type B viruses do not undergo frequent antigenic shifts, which means they have a more stable genetic makeup.

Antigenic Drift: Similar to influenza A, influenza B viruses undergo genetic changes through antigenic drift. These changes result in minor variations in the HA and NA proteins over time. These gradual changes can lead to the emergence of new strains of type B viruses, which may require updates to the seasonal influenza vaccine.

Disease Impact: Influenza B viruses can cause seasonal flu outbreaks, typically during the winter months in temperate regions. The symptoms of influenza B infection are similar to those caused by type A viruses and can include fever, cough, sore throat, body aches, fatigue, and respiratory distress in severe cases. While type B influenza infections can range from mild to severe, they generally cause less severe illness compared to certain strains of influenza A, such as H3N2.

Host Range: Influenza B viruses primarily circulate among humans and do not have the wide host range seen in influenza A viruses. They are less likely to cause zoonotic infections (transmission between animals and humans) and are not commonly associated with epidemics or pandemics.

Vaccination: Influenza B viruses are included in the annual seasonal influenza vaccine along with influenza A viruses. The vaccine is designed to provide protection against the most prevalent strains of influenza B for the given season. Vaccination is recommended to reduce the risk of influenza infection and its associated complications.

Treatment: Antiviral medications, such as oseltamivir (Tamiflu), can be prescribed to treat influenza B infections, particularly in individuals at higher risk of complications or those with severe symptoms.

While influenza B is generally considered less severe than some strains of influenza A, individual experiences with the virus can vary, and severe cases can still occur.

Additional information
Share it